{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:15:21Z","timestamp":1774584921129,"version":"3.50.1"},"reference-count":77,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Background: Manifestations of OAB can considerably diminish the quality of life. Botulinum toxin has emerged as a valuable treatment option in diseases whose symptoms cannot be controlled adequately with other available therapies. The aim of the present study was to compare the subjective quality of life of patients with OAB before the injection of botulinum toxin and three and six months after the intervention. Methods: This study was based on a diagnostic survey with three validated questionnaires, ICIQ-OAB, ICIQ-OABqol, and ICIQ-LUTSqol, and an additional questionnaire developed by the authors to collect sociodemographic characteristics and selected medical data. Results: This study demonstrated significant differences between pre-treatment scores and those at three and six months post injection. At three and six months after the intervention, mean scores for all three instruments (ICIQ-OAB, ICIQ-OABqol, ICIQ-LUTSqol) were significantly lower than the respective pre-treatment values, implying a significant attenuation of OAB symptoms and their lower impact on the quality of life. However, the severity of OAB symptoms and their impact on the quality of life at six months post intervention were significantly higher than at three months, except for the social interaction domain. Conclusions: Botulinum toxin is an effective treatment for OAB.<\/jats:p>","DOI":"10.3390\/toxins16010007","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T05:36:12Z","timestamp":1703136972000},"page":"7","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment"],"prefix":"10.3390","volume":"16","author":[{"given":"Agnieszka A.","family":"Licow-Kami\u0144ska","sequence":"first","affiliation":[{"name":"Department of Neonates, Pathology and Intensive Therapy, Independent Public Specialist Institute of Health \u201cZdroje\u201d, ul. M\u0105czna 4, 70-780 Szczecin, Poland"},{"name":"Department of Children Disease and Children Nursing, Pomeranian Medical University in Szczecin, ul. \u017bo\u0142nierska 48, 71-210 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-5810","authenticated-orcid":false,"given":"Sylwester M.","family":"Cie\u0107wie\u017c","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Ptak","sequence":"additional","affiliation":[{"name":"Independent Subdepartment of Perineological Physiotherapy, Pomeranian Medical University in Szczecin, ul. \u017bo\u0142nierska 54, 51-210 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-9656","authenticated-orcid":false,"given":"Dariusz","family":"Kotl\u0119ga","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, University of Zielona G\u00f3ra, ul. Licealna 9, 65-417 Zielona G\u00f3ra, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-1648","authenticated-orcid":false,"given":"Agnieszka","family":"Brodowska","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","article-title":"Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?","volume":"34","author":"Karimi","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/heapro\/day039","article-title":"The history and promise of holism in health promotion","volume":"34","author":"Michaelson","year":"2019","journal-title":"Health Promot. Int."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Licow, A., Ciecwiez, S., and Brodowska, A. (2022). Quality of life in patients with overactive bladder following botulinum toxin treatment: A preliminary report. Ginekol. Pol.","DOI":"10.5603\/GP.a2022.0105"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/nau.24788","article-title":"Compensatory bladder behaviors (\u201ccoping\u201d) in women with overactive bladder","volume":"41","author":"Reynolds","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00192-021-05033-0","article-title":"Daily symptom associations for urinary urgency and anxiety, depression and stress in women with overactive bladder","volume":"33","author":"Mehr","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.4586","article-title":"CUA guideline on adult overactive bladder","volume":"11","author":"Corcos","year":"2017","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hu, J.C., Hsu, L.N., Lee, W.C., Chuang, Y.C., and Wang, H.J. (2023). Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson\u2019s Disease or Post-Stroke. Toxins, 15.","DOI":"10.3390\/toxins15020166"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/UROS.UROS_16_20","article-title":"Perspectives of medical treatment for overactive bladder","volume":"31","author":"Lin","year":"2020","journal-title":"Urol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/iju.13422","article-title":"Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis","volume":"24","author":"Kato","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/21681805.2013.814707","article-title":"Persistence with first line anticholinergic medication in treatment-na\u00efve overactive bladder patients","volume":"48","author":"Krhut","year":"2014","journal-title":"Scand. J. Urol."},{"key":"ref_11","first-page":"24","article-title":"Jako\u015b\u0107 \u017cycia pacjentek z p\u0119cherzem nadreaktywnym po zastosowaniu toksyny botulinowej\u2014Doniesienie wst\u0119pne [The quality of life of patients with overactive bladder after local injections of botulinum toxin A-a preliminary report]","volume":"81","author":"Rechberger","year":"2010","journal-title":"Ginekol. Pol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/nau.22983","article-title":"Can botox improve night-time overactive bladder symptoms in women?","volume":"36","author":"Cartwright","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.pharep.2018.08.002","article-title":"Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder","volume":"70","author":"Juszczak","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","article-title":"OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice","volume":"32","author":"Hamid","year":"2021","journal-title":"Int. Urogynecol. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Chou, E.C., Chuang, Y.C., Lin, C.C., Hsu, Y.C., Liao, C.H., and Kuo, H.C. (2021). Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan-A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study). Toxins, 13.","DOI":"10.3390\/toxins13120911"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"840695","DOI":"10.3389\/fphar.2022.840695","article-title":"Hengli \u00ae Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"13","author":"Liao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0391560318759258","article-title":"Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience","volume":"85","author":"Tamburro","year":"2018","journal-title":"Urologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/nau.24845","article-title":"Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women","volume":"41","author":"Hendrickson","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs. Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00192-009-0916-8","article-title":"Portuguese validation of the Urinary Incontinence-Specific Quality-of-Life Instrument: I-QOL","volume":"20","author":"Souza","year":"2009","journal-title":"Int. Urogynecol. J. Pelvic. Floor. Dysfunct."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.juro.2017.05.068","article-title":"Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder","volume":"198","author":"Ginsberg","year":"2017","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.sxmr.2017.07.001","article-title":"Urinary Incontinence and Associated Female Sexual Dysfunction","volume":"5","author":"Duralde","year":"2017","journal-title":"Sex. Med. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejogrb.2018.05.002","article-title":"OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome","volume":"225","author":"Balzarro","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/nau.23148","article-title":"Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB","volume":"36","author":"Miotla","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_32","first-page":"235","article-title":"Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: A systematic review and meta-analysis","volume":"33","author":"Shawer","year":"2022","journal-title":"Int. Urogynecol. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00192-018-3653-z","article-title":"A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder","volume":"29","author":"Shepherd","year":"2018","journal-title":"Int. Urogynecol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/cer-2018-0079","article-title":"Cost-effectiveness of overactive bladder treatments: From the US payer perspective","volume":"8","author":"Murray","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10198-015-0737-2","article-title":"OnabotulinumtoxinA in the treatment of overactive bladder: A cost-effectiveness analysis versus best supportive care in England and Wales","volume":"17","author":"Freemantle","year":"2016","journal-title":"Eur. J. Health Econ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ucl.2017.04.012","article-title":"Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity","volume":"44","author":"Kaviani","year":"2017","journal-title":"Urol. Clin. N. Am."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/nau.24248","article-title":"EAU\/ESPU guidelines on the management of neurogenic bladder in children and adolescent part II operative management","volume":"39","author":"Stein","year":"2020","journal-title":"Neurourol. Urodyn."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/JU.0000000000002239","article-title":"The AUA\/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up","volume":"206","author":"Ginsberg","year":"2021","journal-title":"J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.urology.2014.07.046","article-title":"Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications","volume":"84","author":"Nuanthaisong","year":"2014","journal-title":"Urology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/iju.14602","article-title":"Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension","volume":"28","author":"Honda","year":"2021","journal-title":"Int. J. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euf.2016.04.003","article-title":"Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials","volume":"2","author":"Cruz","year":"2016","journal-title":"Eur. Urol. Focus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/nau.22293","article-title":"Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity","volume":"32","author":"Sussman","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1212\/WNL.0b013e3182a2ca4d","article-title":"OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity","volume":"81","author":"Chancellor","year":"2013","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.juro.2018.07.066","article-title":"Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA","volume":"201","author":"Khavari","year":"2019","journal-title":"J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1089\/neu.2020.7115","article-title":"Intradetrusor OnabotulinumtoxinA Injections Ameliorate Autonomic Dysreflexia while Improving Lower Urinary Tract Function and Urinary Incontinence-Related Quality of Life in Individuals with Cervical and Upper Thoracic Spinal Cord Injury","volume":"37","author":"Walter","year":"2020","journal-title":"J. Neurotrauma"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cheng, T., Shuang, W.B., Jia, D.D., Zhang, M., Tong, X.N., Yang, W.D., Jia, X.M., and Li, S. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159307"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/0886022X.2019.1655448","article-title":"Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: Meta-analysis","volume":"41","author":"Wu","year":"2019","journal-title":"Ren. Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4103\/0366-6999.154318","article-title":"Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: A systematic review and meta-analysis","volume":"128","author":"Zhou","year":"2015","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5213\/inj.1732646.323","article-title":"Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis","volume":"21","author":"Yuan","year":"2017","journal-title":"Int. Neurourol. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1590\/S1677-5538.IBJU.2015.02.05","article-title":"OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: A systematic review","volume":"41","author":"Zhang","year":"2015","journal-title":"Int. Braz. J. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"90338","DOI":"10.18632\/oncotarget.20056","article-title":"A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/nau.22934","article-title":"Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study","volume":"36","author":"Kennelly","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/nau.23354","article-title":"Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis","volume":"37","author":"Ni","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Samadzadeh, S., Brauns, R., Rosenthal, D., and Hefter, H. (2021). The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany. Toxins, 13.","DOI":"10.3390\/toxins13020101"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/nau.24588","article-title":"OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children","volume":"40","author":"Austin","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/nau.24778","article-title":"Onabotulinumtoxin A (Botox): A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults","volume":"40","author":"Softness","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.jpedsurg.2020.05.019","article-title":"Safety and efficacy of trigonal BTX-A injections for children with neurological detrusor overactivity secondary to spinal cord injury","volume":"55","author":"Hui","year":"2020","journal-title":"J. Pediatr. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/2090598X.2019.1600993","article-title":"Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study","volume":"17","author":"Gharib","year":"2019","journal-title":"Arab. J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpurol.2019.12.013","article-title":"Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study","volume":"16","author":"Ringoir","year":"2020","journal-title":"J. Pediatr. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/21681805.2017.1329228","article-title":"Single-centre experience with intradetrusor injection of onabotulinumtoxinA: A retrospective study of the years 2003-2012 in a Danish population","volume":"51","author":"Christiansen","year":"2017","journal-title":"Scand. J. Urol."},{"key":"ref_61","unstructured":"Ignaciuk, A. (2019). Toksyna Botulinowa. Dermatologia Kosmetyczna, Edra Urban & Partner. [4th ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/nau.22429","article-title":"The prevalence and risk factors of OAB in middle-aged and old people in China","volume":"33","author":"Wen","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.juro.2017.04.103","article-title":"Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence","volume":"198","author":"Richter","year":"2017","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2017.10.006","article-title":"Refractory urgency urinary incontinence treatment in women: Impact of age on outcomes and complications","volume":"218","author":"Komesu","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamainternmed.2015.2609","article-title":"Urinary Incontinence Before and After Bariatric Surgery","volume":"175","author":"Subak","year":"2015","journal-title":"JAMA. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Hsiao, S.M., Lin, H.H., and Kuo, H.C. (2016). Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147137"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur. Urol. Focus."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1556\/650.2021.32288","article-title":"Hiperakt\u00edv (t\u00falm\u0171k\u00f6d\u0151) h\u00fagyh\u00f3lyag kezel\u00e9se botulinumtoxin-A-ter\u00e1pi\u00e1val [The treatment of overactive bladder syndrome with onabotulinumtoxinA therapy]","volume":"162","author":"Majoros","year":"2021","journal-title":"Orv. Hetil."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00192-017-3440-2","article-title":"What is the true catheterization rate after intravesical onabotulinumtoxinA injection?","volume":"29","author":"Patel","year":"2018","journal-title":"Int. Urogynecol. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00192-016-3212-4","article-title":"Urinary retention in female OAB after intravesical Botox injection: Who is really at risk?","volume":"28","author":"Miotla","year":"2017","journal-title":"Int. Urogynecol. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study","volume":"196","author":"Nitti","year":"2016","journal-title":"J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fsurg.2018.00061","article-title":"Quo Vadis Botulinum Toxin: Normative Constraints and Quality of Life for Patients With Idiopathic OAB?","volume":"5","author":"Mischner","year":"2018","journal-title":"Front. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.urology.2016.10.026","article-title":"Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis","volume":"100","author":"Jaramillo","year":"2017","journal-title":"Urology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00192-020-04230-7","article-title":"A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection","volume":"31","author":"Bickhaus","year":"2020","journal-title":"Int. Urogynecol. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11884-012-0167-2","article-title":"Objective Evaluation of Overactive Bladder: Which Surveys Should I Use?","volume":"8","author":"Shy","year":"2013","journal-title":"Curr. Bladder. Dysfunct. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual. Life Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5455\/2320-6012.ijrms20150301","article-title":"Understanding King\u2019s Health Questionnaire (KHQ) in assessment of female urinary incontinence","volume":"3","author":"Hebbar","year":"2015","journal-title":"Int. J. Res. Med. Sci."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/1\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:20Z","timestamp":1760132360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/1\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["toxins16010007"],"URL":"https:\/\/doi.org\/10.3390\/toxins16010007","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}